Trade Novavax Inc - NVAX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.10 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8.95 |
| Open | 8.94 |
| 1-Year Change | 66.79% |
| Day's Range | 8.87 - 8.94 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 18, 2024 | 8.94 | 0.00 | 0.00% | 8.94 | 9.00 | 8.94 |
| Dec 17, 2024 | 8.94 | -0.15 | -1.65% | 9.09 | 9.25 | 8.87 |
| Dec 16, 2024 | 9.14 | 0.17 | 1.90% | 8.97 | 9.70 | 8.97 |
| Dec 13, 2024 | 8.97 | 0.15 | 1.70% | 8.82 | 9.44 | 8.82 |
| Dec 12, 2024 | 8.97 | 0.20 | 2.28% | 8.77 | 9.23 | 8.63 |
| Dec 11, 2024 | 8.70 | 0.08 | 0.93% | 8.62 | 8.85 | 8.62 |
| Dec 10, 2024 | 8.67 | -0.20 | -2.25% | 8.87 | 9.17 | 8.67 |
| Dec 9, 2024 | 8.98 | 0.15 | 1.70% | 8.83 | 9.19 | 8.83 |
| Dec 6, 2024 | 8.82 | 0.65 | 7.96% | 8.17 | 9.50 | 8.17 |
| Dec 5, 2024 | 8.18 | 0.03 | 0.37% | 8.15 | 8.40 | 8.09 |
| Dec 4, 2024 | 8.15 | -0.23 | -2.74% | 8.38 | 8.78 | 8.11 |
| Dec 3, 2024 | 8.36 | -0.30 | -3.46% | 8.66 | 8.75 | 8.31 |
| Dec 2, 2024 | 8.67 | -0.06 | -0.69% | 8.73 | 8.86 | 8.52 |
| Nov 29, 2024 | 8.66 | 0.09 | 1.05% | 8.57 | 8.81 | 8.46 |
| Nov 28, 2024 | 8.52 | 0.00 | 0.00% | 8.52 | 8.52 | 8.52 |
| Nov 27, 2024 | 8.52 | -0.22 | -2.52% | 8.74 | 8.98 | 8.51 |
| Nov 26, 2024 | 8.77 | -0.47 | -5.09% | 9.24 | 9.24 | 8.59 |
| Nov 25, 2024 | 9.23 | 0.84 | 10.01% | 8.39 | 9.44 | 8.39 |
| Nov 22, 2024 | 8.41 | 0.55 | 7.00% | 7.86 | 8.57 | 7.86 |
| Nov 21, 2024 | 7.98 | 0.01 | 0.13% | 7.97 | 8.29 | 7.90 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Novavax Company profile
Novavax Inc. (NVAX) is a biotechnology company that specialises in the discovery, development and commercialisation of innovative vaccines that prevent serious infectious diseases.
Headquartered in Maryland, United States, the company was founded in 1987.
It has developed a number of vaccines, including:
The Coronavirus vaccine NVX-CoV2373, currently in phase 3 trials.
The seasonal Influenza vaccine NanoFlu™ for adults over the age of 65, currently also in phase 3 trials.
The respiratory Syncytial Virus (RSV) vaccine ResVax™ for infants and maternal immunisation, currently in phase 3 trials, as well as two RSV F Vaccines, one for older adults (phase 2 trials) and one for children until the age of 5 (phase 1 trials).
The Ebola Virus vaccine Ebola GP Vaccine, currently in phase 1 trials.
The company develops its vaccines using genetically engineered three-dimensional nanostructures of recombinant proteins that are critical to disease pathogenesis.
The company is also working on producing immune-stimulating adjuvants at its wholly owned Swedish subsidiary Novavax AB.
Navavax’s key partners and collaborators include:
The Coalition for Epidemic Preparedness Innovations (CEPI), which has been funding the company to develop and manufacture its coronavirus vaccine candidate.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
The Serum Institute of India (SII).
The 2009 joint venture with India’s privately held pharmaceutical company, Cadila Pharmaceuticals Ltd, to develop Novavax VLP vaccine candidates and some Cadila therapeutic vaccine candidates.
The company (ticker: NVAX) went public on the NASDAQ stock exchange in 1995.
| Industry: | Biotechnology & Medical Research (NEC) |
700 Quince Orchard Road
GAITHERSBURG
MARYLAND 20878
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com